123 related articles for article (PubMed ID: 28322244)
1. Targeted therapies: New standard for relapsed ALL.
Hutchinson L
Nat Rev Clin Oncol; 2017 May; 14(5):264. PubMed ID: 28322244
[No Abstract] [Full Text] [Related]
2. Systemic therapy of cholangiocarcinoma: From chemotherapy to targeted therapies.
Schweitzer N; Vogel A
Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):345-53. PubMed ID: 25966433
[TBL] [Abstract][Full Text] [Related]
3. Combinations of targeted therapies in human cancers.
Decaudin D; Le Tourneau C
Aging (Albany NY); 2016 Oct; 8(10):2258-2259. PubMed ID: 27783563
[No Abstract] [Full Text] [Related]
4. Integration of targeted therapies with cytotoxic chemotherapy in the treatment of colorectal cancer.
Chu E
Clin Colorectal Cancer; 2010 Jun; 9 Suppl 1():S6. PubMed ID: 20630852
[No Abstract] [Full Text] [Related]
5. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.
Camicia R; Winkler HC; Hassa PO
Mol Cancer; 2015 Dec; 14():207. PubMed ID: 26654227
[TBL] [Abstract][Full Text] [Related]
6. Targeted therapies for CLL: Practical issues with the changing treatment paradigm.
Jain N; O'Brien S
Blood Rev; 2016 May; 30(3):233-44. PubMed ID: 26776345
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of targeted therapy as monotherapy or combined therapy in patients with relapsed or refractory multiple myeloma: a systematic review and meta-analysis.
Łopuch S; Kawalec P; Wiśniewska N
Hematology; 2015 Jan; 20(1):1-10. PubMed ID: 24580409
[TBL] [Abstract][Full Text] [Related]
8. [Fundamental approaches to the treatment of refractory and relapsed Hodgkin lymphoma].
Filatova LV; Tarasenkova AA; Semiglazova TIu; Gershanovich ML
Vopr Onkol; 2012; 58(4):443-53. PubMed ID: 23607197
[No Abstract] [Full Text] [Related]
9. Molecularly targeted therapy in acute myeloid leukemia.
Gill H; Leung AY; Kwong YL
Future Oncol; 2016 Mar; 12(6):827-38. PubMed ID: 26828965
[TBL] [Abstract][Full Text] [Related]
10. The evolution of bone-targeted therapies: introduction.
Gnant M
Semin Oncol; 2010 Oct; 37 Suppl 2():S1. PubMed ID: 21111243
[No Abstract] [Full Text] [Related]
11. Treatment of Relapsed/Refractory Acute Myeloid Leukemia.
Bose P; Vachhani P; Cortes JE
Curr Treat Options Oncol; 2017 Mar; 18(3):17. PubMed ID: 28286924
[TBL] [Abstract][Full Text] [Related]
12. [State of the art molecular diagnostics and therapy of chronic lymphocytic leukaemia in the era of new targeted therapies].
Gurbity Pálfi T; Fésüs V; Bödör C; Borbényi Z
Orv Hetil; 2017 Oct; 158(41):1620-1629. PubMed ID: 29025288
[TBL] [Abstract][Full Text] [Related]
13. Advanced local therapies for the treatment of limited systemic mCRC.
Sun W
Oncology (Williston Park); 2014 Nov; 28(11):1006-7. PubMed ID: 25403634
[No Abstract] [Full Text] [Related]
14. Biliary tract carcinomas: from chemotherapy to targeted therapy.
Marino D; Leone F; Cavalloni G; Cagnazzo C; Aglietta M
Crit Rev Oncol Hematol; 2013 Feb; 85(2):136-48. PubMed ID: 22809696
[TBL] [Abstract][Full Text] [Related]
15. [Combination strategies in melanoma therapy.].
Spagnolo F
Recenti Prog Med; 2017 Dec; 108(12):503-507. PubMed ID: 29297899
[TBL] [Abstract][Full Text] [Related]
16. The shrinking role of chemotherapy in the treatment of chronic lymphocytic leukemia.
Jacobs RW; Awan FT; Leslie LA; Usmani SZ; Ghosh N
Expert Rev Hematol; 2016 Dec; 9(12):1177-1187. PubMed ID: 27791448
[TBL] [Abstract][Full Text] [Related]
17. Combining molecular targeted therapies: clinical experience.
Pivot X; Bedairia N; Thiery-Vuillemin A; Espie M; Marty M
Anticancer Drugs; 2011 Sep; 22(8):701-10. PubMed ID: 21467916
[TBL] [Abstract][Full Text] [Related]
18. Inotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemia.
Thota S; Advani A
Eur J Haematol; 2017 May; 98(5):425-434. PubMed ID: 28152223
[TBL] [Abstract][Full Text] [Related]
19. Targeted therapy vs chemotherapy: which has had more impact on survival in lung cancer? The significant impact of chemotherapy in lung cancer.
Socinski MA
Clin Adv Hematol Oncol; 2014 Nov; 12(11):763, 767-8. PubMed ID: 25674716
[No Abstract] [Full Text] [Related]
20. Re: Himisha Beltran, Tomasz M. Beer, Michael A. Carducci, et al. New therapies for castration-resistant prostate cancer: efficacy and safety. Eur urol 2011;60:279-90.
Braillon A
Eur Urol; 2011 Oct; 60(4):e33. PubMed ID: 21767907
[No Abstract] [Full Text] [Related]
[Next] [New Search]
